KNX 018
Alternative Names: KNX-018Latest Information Update: 17 Jan 2022
At a glance
- Originator Kenox Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-small cell lung cancer
Most Recent Events
- 20 Dec 2021 Preclinical trials in Non-small cell lung cancer in USA (Inhalation)
- 20 Dec 2021 Kenox Pharmaceuticals plans to submit an Investigative New Drug Application (IND) to US FDA in 2022
- 14 Dec 2021 Kenox Pharmaceuticals receives a positive response from the US FDA supporting the planned CMC, non-clinical and clinical development strategy, prior to December 2021